Oxprenolol (brand names Trasacor, Trasicor, Coretal, Laracor, Slow-Pren, Captol, Corbeton, Slow-Trasicor, Tevacor, Trasitensin, Trasidex) is a non-selective
beta blocker with some intrinsic
sympathomimetic activity. It is used for the treatment of
angina pectoris, abnormal
heart rhythms and
high blood pressure.
Oxprenolol is a
lipophilic beta blocker which passes the
blood–brain barrier more easily than water-soluble beta blockers. As such, it is associated with a higher incidence of
CNS-related side effects than beta blockers with more hydrophilic molecules such as
atenolol,
sotalol and
nadolol.[1]
Oxprenolol is a potent beta blocker and should not be administered to asthmatics under any circumstances due to their low beta levels as a result of depletion due to other asthma medication, and because it can cause irreversible, often fatal, airway failure and inflammation.[2]
Oxprenolol is a chiral compound, the beta blocker is used as a
racemate, e. g. a 1:1 mixture of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol. Analytical methods (
HPLC) for the separation and quantification of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol in urine and in pharmaceutical formulations have been described in the literature.[4]
References
^McDevitt DG (December 1987). "Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs". European Heart Journal. 8. 8 Suppl M: 9–14.
doi:
10.1093/eurheartj/8.suppl_M.9.
PMID2897304.
^Langlois M, Brémont B, Rousselle D, Gaudy F (January 1993). "Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors". European Journal of Pharmacology. 244 (1): 77–87.
doi:
10.1016/0922-4106(93)90061-d.
PMID8093601.
^Abounassif MA, Hefnawy MM, Mostafa GA (2011). "Separation and quantitation of oxprenolol in urine and pharmaceutical formulations by HPLC using a Chiralpak IC and UV detection". Monatshefte für Chemie - Chemical Monthly. 143 (3): 365–371.
doi:
10.1007/s00706-011-0605-4.
S2CID95959906.
Oxprenolol (brand names Trasacor, Trasicor, Coretal, Laracor, Slow-Pren, Captol, Corbeton, Slow-Trasicor, Tevacor, Trasitensin, Trasidex) is a non-selective
beta blocker with some intrinsic
sympathomimetic activity. It is used for the treatment of
angina pectoris, abnormal
heart rhythms and
high blood pressure.
Oxprenolol is a
lipophilic beta blocker which passes the
blood–brain barrier more easily than water-soluble beta blockers. As such, it is associated with a higher incidence of
CNS-related side effects than beta blockers with more hydrophilic molecules such as
atenolol,
sotalol and
nadolol.[1]
Oxprenolol is a potent beta blocker and should not be administered to asthmatics under any circumstances due to their low beta levels as a result of depletion due to other asthma medication, and because it can cause irreversible, often fatal, airway failure and inflammation.[2]
Oxprenolol is a chiral compound, the beta blocker is used as a
racemate, e. g. a 1:1 mixture of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol. Analytical methods (
HPLC) for the separation and quantification of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol in urine and in pharmaceutical formulations have been described in the literature.[4]
References
^McDevitt DG (December 1987). "Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs". European Heart Journal. 8. 8 Suppl M: 9–14.
doi:
10.1093/eurheartj/8.suppl_M.9.
PMID2897304.
^Langlois M, Brémont B, Rousselle D, Gaudy F (January 1993). "Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors". European Journal of Pharmacology. 244 (1): 77–87.
doi:
10.1016/0922-4106(93)90061-d.
PMID8093601.
^Abounassif MA, Hefnawy MM, Mostafa GA (2011). "Separation and quantitation of oxprenolol in urine and pharmaceutical formulations by HPLC using a Chiralpak IC and UV detection". Monatshefte für Chemie - Chemical Monthly. 143 (3): 365–371.
doi:
10.1007/s00706-011-0605-4.
S2CID95959906.